Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phe nyl}-1,3,4,5-tetrahydro-6H-azepino[5,4, 3-cd]indol-6-one

Details for Australian Patent Application No. 2005286191 (hide)

Owner Pfizer Inc. Cancer Research Technology Ltd.

Inventors Borer, Bennett Chaplin; Mitchell, Mark Bryan; Nayyar, Naresh; Li, Yi; Guo, Ming; Chu, Jan-Jon; Srirangam, Aparna Nadig; Liu, Jia; Wu, Zhen-Ping

Agent Shelston IP

Pub. Number AU-B-2005286191

PCT Pub. Number WO2006/033007

Priority 60/679,296 09.05.05 US; 60/612,459 22.09.04 US

Filing date 12 September 2005

Wipo publication date 30 March 2006

Acceptance publication date 17 November 2011

International Classifications

C07D 487/06 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

22 March 2007 PCT application entered the National Phase

  PCT publication WO2006/033007 Priority application(s): WO2006/033007

17 November 2011 Application Accepted

  Published as AU-B-2005286191

15 March 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005286197-Substitution boxes

2005286190-Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor